Insider Selling: Immunovant, Inc. (NASDAQ:IMVT) Insider Sells 60,490 Shares of Stock

Immunovant, Inc. (NASDAQ:IMVT – Get Rating) insider Julia G. Butchko sold 60,490 shares of the business’s stock in a transaction dated Wednesday, January 11th. The stock was sold at an average price of $16.79, for a total transaction of $1,015,627.10. Following the completion of the sale, the insider now owns 331,419 shares in the company, valued at $5,564,525.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Immunovant Price Performance

NASDAQ:IMVT opened at $18.60 on Friday. Immunovant, Inc. has a fifty-two week low of $3.14 and a fifty-two week high of $20.24. The stock’s 50-day moving average is $15.23 and its two-hundred day moving average is $9.37. The stock has a market cap of $2.40 billion, a PE ratio of -12.16 and a beta of 1.03.

Immunovant (NASDAQ:IMVT – Get Rating) last released its earnings results on Friday, November 4th. The company reported ($0.41) earnings per share for the quarter, meeting the consensus estimate of ($0.41). On average, equities research analysts anticipate that Immunovant, Inc. will post -1.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on IMVT shares. Truist Financial lifted their price target on Immunovant to $30.00 in a research note on Thursday, November 17th. Wells Fargo & Company raised Immunovant from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $10.00 to $27.00 in a research note on Monday, January 2nd. HC Wainwright lifted their price target on Immunovant from $16.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, November 7th. UBS Group cut Immunovant from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $7.00 to $5.00 in a research note on Monday, September 26th. Finally, Chardan Capital lifted their price target on Immunovant from $12.00 to $19.00 and gave the stock a “buy” rating in a research note on Monday, November 7th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $16.86.

Institutional Investors Weigh In On Immunovant

Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. lifted its holdings in shares of Immunovant by 0.9% during the 1st quarter. BlackRock Inc. now owns 3,353,866 shares of the company’s stock valued at $18,479,000 after buying an additional 28,865 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Immunovant during the 3rd quarter valued at about $10,978,000. Federated Hermes Inc. lifted its holdings in shares of Immunovant by 281.2% during the 1st quarter. Federated Hermes Inc. now owns 1,903,894 shares of the company’s stock valued at $10,491,000 after buying an additional 1,404,404 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Immunovant by 11.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,058,459 shares of the company’s stock valued at $5,906,000 after buying an additional 112,979 shares during the last quarter. Finally, State Street Corp lifted its holdings in shares of Immunovant by 6.8% during the 2nd quarter. State Street Corp now owns 892,680 shares of the company’s stock valued at $3,481,000 after buying an additional 56,938 shares during the last quarter. 32.77% of the stock is currently owned by institutional investors and hedge funds.

About Immunovant

(Get Rating)

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia.